Owlet, Inc.
OWLT Healthcare Medical Devices
In the quarter to June 2026, revenue grew 29.9%, EPS grew 97.9%, free cash flow grew 55.7% and total debt fell 16.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow OWLT
Owlet, Inc. (OWLT) EV/Sales
As of 16 October 2026, Owlet, Inc. (OWLT) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.0× (September 2021) to 6.9× (June 2022); the current reading is higher than 54% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | 391.57% |
| FY2024 | 0.5× | (41.06%) |
| FY2023 | 0.9× | (13.70%) |
| FY2022 | 1.0× | (15.72%) |
| FY2021 | 1.2× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.3× | 14.78% |
| Mar 2026 | 1.1× | (55.77%) |
| Dec 2025 | 2.5× | 80.87% |
| Sep 2025 | 1.4× | (4.62%) |
| 19 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RXST RxSight, Inc. compare | 0.0× |
| INGN Inogen, Inc compare | 0.2× |
| QTRX Quanterix Corporation compare | 0.3× |
| OWLT Owlet, Inc. | 0.9× |
| ZOMDF Zomedica Corp. compare | 0.9× |
| STIM Neuronetics, Inc. compare | 1.2× |
| MXCT MaxCyte, Inc. compare | 1.2× |
| APYX Apyx Medical Corporation compare | 2.2× |
| LUCD Lucid Diagnostics Inc. compare | 14.3× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)